A spray that halts blood in seconds? Scientists tested it, and what happened next could change battlefield medicine forever.
Medical Device Network on MSN
BioStem acquires BioTissue’s surgical and wound care assets in $40M deal
BioStem said the acquisition will support its advancement into ‘high value’ adjacent market segments.
Vietnam Investment Review on MSN
Study confirms myriad value in trauma surgery
AUCKLAND, New Zealand, Jan. 23, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, the Myriad Augmented Soft Tissue ...
The FDA has approved Fesilty (fibrinogen, human-chmt) for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency (CFD), including hypo- or ...
Accelerates expansion of BioStem’s commercial organization through integration of an experienced national sales forceExpands access to major GPO ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
Healthcare company Solventum agreed to acquire Acera Surgical for $725 million in cash, further expanding into the regenerative wound care market. The agreement also calls for up to $125 million in ...
Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space, a part of the broader regenerative tissue matrices category within acute care settings, a $900 million ...
Solventum has entered into an agreement to acquire Acera Surgical, a developer of materials for regenerative wound care, for $850 million. The deal will include an upfront cash payment of $725 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback